Patient Flow Articles & Analysis
13 news found
IRVINE, CA / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at ...
Gesynta Pharma AB today announces that all patients have been recruited for the company's clinical Phase II study with the drug candidate GS-248, which is being evaluated as a treatment for the rare disorder systemic sclerosis.The study is intended to demonstrate proof-of-concept and to evaluate the safety profile of GS-248. Top-line data is expected in the fall of 2022. Systemic ...
New Current Procedural Terminology (CPT®) III code establishes a reimbursement pathway for the VenoValve The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg There are currently no effective treatments for patients with deep venous CVI The VenoValve is currently being evaluated in leading ...
Expanding patent portfolio bolsters protection of the Company’s lead product The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg There are currently no effective treatments for patients with deep venous CVI The VenoValve is currently being evaluated in leading hospitals throughout the U.S. in ...
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. SNG001 demonstrated a favourable safety profile and was well ...
eNOfit™, Third Pole’s novel nitric oxide mobile-wearable device designed to provide “on-the-go” treatment for patients suffering from severe COPD and ILD, to enter clinical trials in the second half of this year Funding will support device optimization and clinical trials; Pivotal trial data expected in the second half of 2023 Third Pole Therapeutics, a privately ...
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the TearCare® System for the treatment of meibomian gland dysfunction (MGD), the leading cause of dry eye disease (DED). The indication ...
Total MRI scan volume at the HMCA-managed sites increased 11.6 % to 48,469 scans for the quarter ending September 30, 2021 versus the same quarter one year earlier. This is highest quarterly total in the Company’s history. Diluted Net Income per Common Share increased 53% to $0.55 for the quarter ended September 30, 2021 versus the same quarter one year earlier. Total Revenues-Net ...
The novel drug Revacept can reduce heart attacks and strokes more efficient and safer than previous standard therapies. This is the result of a study in an investigator initiated study in patients carried out with the German Center for Heart and Circulation Research (DZHK). The study was recently published in JAMA Cardiology. With Revacept severe complications such as heart attacks and stroke in ...
The funds will be used to pursue the commercialization of Flosonics Medical’s wireless Doppler ultrasound patch in addition to new product development Flosonics Medical recently announced the close of a $14 million USD funding round led by Arboretum Ventures in partnership with existing investors iGan Partners and Genesys Capital. The Canadian medical device company headquartered in ...
Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), today announced that it has closed a $24 million Series B financing round. The funding was led by Invus Opportunities and included participation from F-Prime Capital, Medical Technology Venture Partners, Golden Seeds, Astia ...
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced Phil Posa has joined its executive management team as Senior Vice President of U.S. & International Sales. Posa, who brings more than 30 years of experience in the pharmaceutical, medical device and regenerative spaces, ...
Delayed test results often mean HIV patients in Mozambique fail to get timely treatment, but new technology is reducing the need to send tests to far away laboratories, and speeding up test results and HIV treatment. Mozambique's Ministry of Health has increasingly begun experimenting with new technology to make diagnosing and monitoring HIV patients quicker and easier. After a successful 2009 ...